New Pipeline PIPELINE Discovery Validation/Optimization In Vivo POC IND Studies Phase 1 Platform: Multiple Myeloma (CD38 Targeting) 79% Candidate/Program: KP1237 (ARM™) + Autlogous NK cells • Patient Population: Post Transplant 3Q2020 P1/2 70% Candidate/Program: KP1237(ARM™) • Patient Population: Darzalex® R/R 3Q2020 40% Candidate/Program: KP1237 (ARMTM) + Allogeneic NK cells • Patient Population: Post-Transplant • Collaborator: Celularity, GC LabCell Platform: COVID-19 (Spike Protein Targeting) 20% Candidate/Program: COVID-19 MATETM HGM • Patient Population: Prophylactic or Hospitalized 23% Candidate/Program: COVID-19 ARMTM • Patient Population: Hospitalized 25% Candidate/Program: COVID-19 ARMTM • Patient Population: Hospitalized Collaborator: Celularity, GC LabCell
